Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation
Status:
Terminated
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
During the pre-transplantation phase (following completion of consolidation chemotherapy),
patients will begin to receive G-CSF at 10 mcg/kg twice daily; leukapheresis will also be
given until a target goal for recipient body weight is obtained, or up to a maximum of 5
days. Conditioning/Preparative therapy will follow PBSC collection for up to 30 days with
Busulfan IV daily x 4 days; subsequent doses will be adjusted based on pharmacokinetic
(plasma level)monitoring. Following 1 day of rest, stem cell reinfusion will begin with
supportive care. During follow-up, patients will be monitored out to 730 days.
Phase:
N/A
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute